BION
Bion Environmental Technologies provides environmental solutions to Concentrated Animal Feeding Operations (CAFO's). The Company's technology reduces excess nutrients from CAFO waste that fuel toxic algae blooms and dead zones in the Chesapeake Bay, Gulf of Mexico, and the Great Lakes. It was founded in 1989 and headquartered in Crestone, Colorado.
BION
Industry:
Agriculture Biotechnology Environmental Consulting Health Care Information Technology Livestock
Founded:
1989-01-01
Address:
Crestone, Colorado, United States
Country:
United States
Website Url:
http://www.biontech.com
Total Employee:
11+
Status:
Active
Contact:
(212)758-6622
Total Funding:
890 K USD
Technology used in webpage:
ReCAPTCHA ReCAPTCHA V2 ReCAPTCHA V3 3 To 9 CcTLD Redirects
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.biontech.com Semrush global rank: 532.8 K Semrush visits lastest month: 90.53 K
- Host name: a23-73-207-6.deploy.static.akamaitechnologies.com
- IP address: 23.73.207.6
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Bion"
BioNTech | Our mission: basic research in mRNA …
BioNTech works closely with some of the world’s most established pharmaceutical companies and non-profit organizations to drive breakthroughs in medical science, therapeutical innovations, and improvement of quality of …See details»
From Discovery to Delivery – Meet our Senior Team - BioNTech
Having joined BioNTech in 2019, the year in which BioNTech went public, Lisa has since played a key role in building, expanding and professionalizing the finance organization. She has been …See details»
BioNTech - Wikipedia
BioNTech was founded in 2008 based on research by UÄŸur Åžahin, Özlem Türeci, and Christoph Huber, with a seed investment of €150 million from MIG Capital, a Munich-based venture capital firm, and AT Impf, an investment vehicle under control of the single family office of German billionaire twin brothers, Andreas and Thomas Strüngmann. The company's activities focus on the development and production of technologies and drugs for individualized cancer immunotherapy. …See details»
Management Report on the Group and the Company for the 2020 …
BioNTech - Crunchbase Company Profile & Funding
BioNTech creates protein-based therapeutics, including antibodies and antibody-drug conjugates, to address various tumor types and bacterial infections. Small Molecule Immunomodulators BioNTech develops small molecules to enhance …See details»
Inside the hunt for a Covid-19 vaccine: how BioNTech …
Nov 13, 2020 For BioNTech, the timing of Sars-Cov-2’s arrival is just one of several serendipitous events that led to the company’s unlikely success. ... By the time the World Health Organization declared ...See details»
Inside BioNTech's Factory Where Pfizer Vaccine Is …
Apr 19, 2021 Ultimately, the plant will churn out 1 billion doses a year, and BioNTech is working with Pfizer, which oversaw the final human testing that resulted in the vaccine’s authorization in the U.K ...See details»
Pfizer–BioNTech COVID-19 vaccine - Wikipedia
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [2] [33] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech …See details»
BioNTech | The BioNTech Board
She was also responsible for building a new global oncology organization following a company-wide transformation. At Bristol-Myers Squibb Co., she held a pivotal role in evolving the company’s U.S. oncology strategy, resulting in …See details»
Pfizer and BioNTech Announce Further Details on Collaboration to ...
Pfizer and BioNTech to jointly develop COVID-19 vaccine, initially in the United States and Europe, and scale-up manufacturing capacity to support global supply Potential to supply …See details»
WHO issues its first emergency use validation for a COVID-19 …
Dec 31, 2020 The World Health Organization (WHO) today listed the Comirnaty COVID-19 mRNA vaccine for emergency use, making the Pfizer/BioNTech vaccine the first to receive …See details»
Shot of a Lifetime: How Pfizer and BioNTech Developed and …
Oct 15, 2021 On March 11, 2020 the World Health Organization declared COVID-19 a pandemic. 1 Just six days later, on March 17, Pfizer signed a letter of intent with BioNTech to …See details»
Shot of a Lifetime: How Pfizer and BioNTech Developed and …
On March 11, 2020 the World Health Organization declared COVID-19 a pandemic1. Just six days later, on March 17, Pfizer signed a letter of intent with BioNTech to co-develop a potential …See details»
The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: What you …
Aug 18, 2022 The Pfizer BioNTech vaccine against COVID-19 has very high efficacy against severe disease and moderate efficacy against symptomatic SARS-CoV-2 infection. What is …See details»
BioNTech: A company with social responsibility
BioNTech commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2021 base year. BioNTech commits that 72% of its suppliers by emissions covering purchased …See details»
Background document on mRNA vaccine BNT162b2 (Pfizer …
Jan 14, 2021 This background document on the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 has been prepared by the Working Group on COVID-19 Vaccines of the Strategic …See details»
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for …
Dec 9, 2022 The vaccine candidate is based on BioNTech’s proprietary mRNA platform technology and contains mRNA strands encoding the wild-type spike protein of SARS-CoV-2 …See details»
BioNTech | Global Health Commitment
BioNTech aspires to translate science into survival by addressing pressing health challenges we face as a global society. Based on our mRNA technology and our experience in the field of …See details»
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With …
Jul 27, 2022 The Pfizer-BioNTech COVID-19 Vaccine, BNT162b2, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. …See details»